Ken Griffin Xilio Therapeutics, Inc. Transaction History

Citadel Advisors LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.5 - $2.5 $25,709 - $128,547	51,419 New	51,419 $28,000
Q2 2023 Aug 14, 2023	SELL	$2.55 - $3.46 $149,139 - $202,361	-58,486 Reduced 81.64%	13,149 $34,000
Q1 2023 May 15, 2023	BUY	$2.66 - $4.28 $190,549 - $306,597	71,635 New	71,635 $227,000

10M

Ticker XLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,471,600
Market Cap $26.1M
Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.